The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Northern Europe The TRANS-North Study
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
Trafermin is a recombinant human basic fibroblast growth factor (bFGF; original development
code, KCB-1), which is manufactured by genetic engineering using Escherichia coli by Kaken
Pharmaceutical Co., Ltd. (Tokyo, Japan). Trafermin 0.01% cutaneous spray product kit
consisting of a glass bottle containing lyophilized trafermin, a glass bottle with solvent
for solution and a spray part to fit the glass bottle after reconstitution of the final
product.
We conduct a multinational, randomized, double-blind, placebo controlled, parallel-group,
multicentre study consisting of a placebo run-in phase (2w), a treatment phase (max. 12w) and
a follow-up phase (3mo+6mo). The primary objective of the study is to demonstrate a superior
wound closure rate of diabetic foot ulcers (DFUs) of neuropathic origin after a maximum of 12
weeks topical daily application of trafermin 0.01% spray compared with placebo, in addition
to best local care (off-loading, dressings). Approximately 210 patients will be randomized
and it is planned that this study will be conducted at approximately 40 investigational sites
in Europe.